Evidence map›Paper›PMID 36327007›Full record

ReviewInternational urology and nephrology2023

Sarcopenia and cardiovascular disease in patients with and without kidney disease: what do we know?

Ozkan Gungor, Mustafa Sevinc, Sena Ulu, Ismail Kocyigit

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Ozkan GungorNephrology Department, Medical Faculty, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
Mustafa SevincNephrology Department, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. musevinc@hotmail.com.ORCID http://orcid.org/0000-0003-2804-4884
Sena UluNephrology Department, Medical Faculty, Bahcesehir University, Istanbul, Turkey.
Ismail KocyigitNephrology Department, Medical Faculty, Erciyes University, Kayseri, Turkey.
Bahçeşehir University · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRErciyes University · TRKahramanmaraş Sütçü İmam University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) incidence is high in patients with chronic kidney disease (CKD) and is the most frequent cause of mortality in this population. Advanced age, hypertension, uremic toxins, endothelial dysfunction, atherosclerosis, hyperhomocysteinemia, oxidative stress, and inflammation are among the leading causes of increased CVD in advanced stages of CKD. Although defined as a decrease in muscle strength associated with aging, sarcopenia is also prevalent in CKD patients. Sarcopenia causes physical disability, low quality of life, and mortality. Regular exercise and nutritional supplementation may slow the progression of sarcopenia. Recent studies have shown that sarcopenia increases the risk of CVD and mortality in people with or without kidney disease. This review discusses the relationship between sarcopenia and CVD in light of the current literature.

Indexed as

Cardiovascular DiseasesRenal Insufficiency, ChronicSarcopeniaHumansMuscle StrengthQuality of LifeCardiovascular diseaseKidneyKidney patientsMuscleSarcopenia

Identifiers

PMID36327007
OpenAlexW4308057448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.